Psoriasis Clinical Trial
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
Full Description
This study will consist of a 4 week screening period, 12 week treatment period, and a 4 week follow up period for a total of 20 weeks. Each participant will be randomized to receive ESK-001 or placebo daily for 12 weeks. An open label extension study will be available for those patients who complete the study.
Eligibility Criteria
Inclusion Criteria:
Total body weight >40 kg (88 lb)
Men and woman age 18-75
Men and Women must use highly effective methods of contraception for the entirety of the study
Exclusion Criteria:
History of malignancy within the last 5 years
Positive for HIV, Hepatitis B or C
History of tuberculosis
Diagnosis of non-plaque psoriasis
Patients with QTcF >450 msec (males) or >470 msec (females) at screening
Live vaccines
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 53 Locations for this study
Birmingham Alabama, 35205, United States
Phoenix Arizona, 85032, United States
Rogers Arkansas, 72758, United States
Encinitas California, 92024, United States
Fremont California, 94538, United States
Los Angeles California, 90033, United States
Los Angeles California, 90045, United States
San Diego California, 92123, United States
Santa Monica California, 90404, United States
Sherman Oaks California, 91403, United States
Brandon Florida, 33511, United States
Brandon Florida, 33756, United States
Fort Lauderdale Florida, 33308, United States
Hialeah Florida, 33012, United States
Miami Florida, 33175, United States
Tampa Florida, 33613, United States
Macon Georgia, 31217, United States
Sandy Springs Georgia, 30328, United States
Rolling Meadows Illinois, 60008, United States
Indianapolis Indiana, 46250, United States
South Bend Indiana, 46617, United States
Overland Park Kansas, 66210, United States
Louisville Kentucky, 40241, United States
Owensboro Kentucky, 42303, United States
Rockville Maryland, 20850, United States
Bay City Michigan, 48706, United States
Clarkston Michigan, 48346, United States
Warren Michigan, 48088, United States
New Brighton Minnesota, 55112, United States
Las Vegas Nevada, 89148, United States
Portsmouth New Hampshire, 03801, United States
Oklahoma City Oklahoma, 73170, United States
Portland Oregon, 97223, United States
Philadelphia Pennsylvania, 19103, United States
Rapid City South Dakota, 57702, United States
Houston Texas, 77056, United States
San Antonio Texas, 78213, United States
South Jordan Utah, 84095, United States
Edmonton Alberta, T6G 1, Canada
Surrey British Columbia, V3V 0, Canada
Winnipeg Manitoba, R3M 3, Canada
London Ontario, N6H 5, Canada
Mississauga Ontario, L4Y 4, Canada
North Bay Ontario, P1B 3, Canada
Oakville Ontario, L6J 7, Canada
Toronto Ontario, M3H 5, Canada
Waterloo Ontario, N2J 1, Canada
Quebec City Quebec, G1V 4, Canada
Svitavy Pardubice, 568 0, Czechia
Novy Jicin , 741 0, Czechia
Pardubice , 530 0, Czechia
Praha 10 , 100 0, Czechia
Praha 10 , 100 3, Czechia
How clear is this clinincal trial information?